At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,323 enrolled
Drug / intervention
Alogliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin for Diabetes Mellitus. Completed, enrolled 3,323 participants across 114 sites in 12 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Brazil, Chile, Czechia, Dominican Republic, Germany, Guatemala, Netherlands, Peru, Poland, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMar 2006
Primary CompletionNov 2011
TodayJul 2026
First PostedMar 23, 2006
Enrollment StartMar 1, 2006
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 20.3 years ago
Interventions
Alogliptindrug
Alogliptin tablets.